Pharmacologic Therapies for Obesity

Gastroenterology Clinics of North America

Volumn 39, Issue 1, 2010, Pages 69-79

  Kaplan, Lee M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Obesity treatment; Pharmacology treatments obesity; Weight loss medication

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMFEBUTAMONE; AMFEPRAMONE; ANTIHYPERTENSIVE AGENT; BENZPHETAMINE; CLOZAPINE; DEXFENFLURAMINE; EPHEDRINE; EXENDIN 4; FENFLURAMINE; LORCASERIN; METFORMIN; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; OLANZAPINE; PHENDIMETRAZINE; PHENTERMINE; PHENYLPROPANOLAMINE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; STEROID HORMONE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZONISAMIDE;

AGITATION; ANTICHOLINERGIC SYNDROME; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIET RESTRICTION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG POTENTIATION; DRUG WITHDRAWAL; ENDOSCOPIC SURGERY; FECES INCONTINENCE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; LIVER INJURY; MALABSORPTION; METABOLIC BONE DISEASE; MIGRAINE; MONOTHERAPY; MOOD DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL COUNSELING; OBESITY; PERIPHERAL NEUROPATHY; REVIEW; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; STARVATION; STEATORRHEA; STROKE; TACHYCARDIA; TREATMENT INDICATION; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BARIATRIC SURGERY; BENZAZEPINES; BUPROPION; CYCLOBUTANES; EPHEDRINE; FENFLURAMINE; HUMANS; LACTONES; NALTREXONE; OBESITY; PHENTERMINE; WEIGHT GAIN; WEIGHT LOSS;

EID: 77349115193     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.01.001     Document Type: Review

References (39)

1. Bray G.A. Medications for weight reduction. Endocrinol Metab Clin North Am 37 (2008) 923-942
2. Chakrabarti R. Pharmacotherapy of obesity: emerging drugs and targets. Expert Opin Ther Targets 13 (2009) 195-207
3. Bray G.A. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab 93 (2008) S81-S88
4. Padwal R., Li S.K., and Lau D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27 (2003) 1437-1446
5. Bray G.A., and Greenway F.L. Pharmacological treatment of the overweight patient. Pharmacol Rev 59 (2007) 151-184
6. Padwal R., Li S.K., and Lau D.C. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev (2003) CD004094
7. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obes Res 6 Suppl 2 (1998) 51S-209S
8. Leung W.Y., Thomas G.N., Chan J.C., et al. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 25 (2003) 58-80
9. Jain A.K., Kaplan R.A., Gadde K.M., et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 10 (2002) 1049-1056
10. Harborne L.R., Sattar N., Norman J.E., et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 90 (2005) 4593-4598
11. Mafong D.D., and Henry R.R. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep 10 (2008) 55-60
12. Astrup A., and Toubro S. Topiramate: a new potential pharmacological treatment for obesity. Obes Res 12 Suppl (2004) 167S-173S
13. Gadde K.M., Franciscy D.M., Wagner II H.R., et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289 (2003) 1820-1825
14. Bray G.A., and Ryan D.H. Drug treatment of the overweight patient. Gastroenterology 132 (2007) 2239-2252
15. Neovius M., Johansson K., and Rossner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 9 (2008) 420-427
16. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997) 581-588
17. Dahl C.F., and Allen M.R. Regression and progression of valvulopathy associated with fenfluramine and phentermine. Ann Intern Med 136 (2002) 489
18. Volmar K.E., and Hutchins G.M. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 125 (2001) 1555-1561
19. Neovius M., and Narbro K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int J Obes (Lond) 32 (2008) 1752-1763
20. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 (2005) 2111-2120
21. Bray G.A. Are non-prescription medications needed for weight control?. Obesity (Silver Spring) 16 (2008) 509-514
22. Eliasson B., Gudbjornsdottir S., Cederholm J., et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond) 31 (2007) 1140-1147
23. Smith S.R., Aronne L.J., Burns C.M., et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31 (2008) 1816-1823
24. Idelevich E., Kirch W., and Schindler C. Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis 3 (2009) 75-90
25. Jeon M.K., and Cheon H.G. Promising strategies for obesity pharmacotherapy: melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists. Curr Top Med Chem 9 (2009) 504-538
26. Mayer M.A., Hocht C., Puyo A., et al. Recent advances in obesity pharmacotherapy. Curr Clin Pharmacol 4 (2009) 53-61
27. Lee M.W., and Fujioka K. Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother 10 (2009) 1841-1845
28. Greenway F.L., Dunayevich E., Tollefson G., et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 94 (2009) 4898-4906
29. Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs 10 (2009) 1117-1125
30. Plodkowski R.A., Nguyen Q., Sundaram U., et al. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 10 (2009) 1069-1081
31. Klonoff D.C., and Greenway F. Drugs in the pipeline for the obesity market. J Diabetes Sci Technol 2 (2008) 913-918
32. Gadde K.M., and Allison D.B. Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes 16 (2009) 353-358
33. Isidro M.L., and Cordido F. Drug treatment of obesity: established and emerging therapies. Mini Rev Med Chem 9 (2009) 664-673
34. Weintraub M., Sundaresan P.R., Schuster B., et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin Pharmacol Ther 51 (1992) 608-614
35. Drug Enforcement Administration (DEA), Justice. Implementation of the comprehensive methamphetamine control of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule. Fed Regist 67 (2002) 14853-14862
36. Food and Drug Administration, HHS. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed Regist 69 (2004) 6787-6854
37. Shank R.P., and Maryanoff B.E. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 14 (2008) 120-142
38. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
39. Hatoum I.J., Stein H.K., Merrifield B.F., et al. Capacity for physical activity predicts weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring) 17 (2009) 92-99